Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.

Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA.

J Acquir Immune Defic Syndr. 2019 Apr 29. doi: 10.1097/QAI.0000000000002094. [Epub ahead of print]

PMID:
31107304
2.

Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up.

Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferrière V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2019 May 1;33(6):1013-1022. doi: 10.1097/QAD.0000000000002156.

3.

Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy.

Kahn-Kirby AH, Amagata A, Maeder CI, Mei JJ, Sideris S, Kosaka Y, Hinman A, Malone SA, Bruegger JJ, Wang L, Kim V, Shrader WD, Hoff KG, Latham JC, Ashley EA, Wheeler MT, Bertini E, Carrozzo R, Martinelli D, Dionisi-Vici C, Chapman KA, Enns GM, Gahl W, Wolfe L, Saneto RP, Johnson SC, Trimmer JK, Klein MB, Holst CR.

PLoS One. 2019 Mar 28;14(3):e0214250. doi: 10.1371/journal.pone.0214250. eCollection 2019.

4.

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care.

Rossi C, Young J, Martel-Laferrière V, Walmsley S, Cooper C, Wong A, Gill MJ, Klein MB; Canadian Co-Infection Cohort Investigators .

Open Forum Infect Dis. 2019 Feb 13;6(3):ofz055. doi: 10.1093/ofid/ofz055. eCollection 2019 Mar.

5.

Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP.

Younger J, Raboud J, Szadkowski L, Harrigan R, Walmsley S, Bayoumi AM, Klein MB, Cooper C, Burchell AN, Loutfy M, Hull M, Wong A, Thomas R, Hogg R, Montaner J, Tsoukas C, Antoniou T; Canadian Observational Cohort Collaboration.

Antivir Ther. 2019 Mar 15. doi: 10.3851/IMP3302. [Epub ahead of print]

PMID:
30873953
6.

Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.

Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Lo Re V, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Palella FJ Jr, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ; North American AIDS Cohort Collaboration on Research and Design.

Lancet HIV. 2019 Feb;6(2):e93-e104. doi: 10.1016/S2352-3018(18)30295-9. Epub 2019 Jan 22. Erratum in: Lancet HIV. 2019 Apr 2;:.

PMID:
30683625
7.

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.

Costiniuk CT, Saneei Z, Routy JP, Margolese S, Mandarino E, Singer J, Lebouché B, Cox J, Szabo J, Brouillette MJ, Klein MB, Chomont N, Jenabian MA.

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

8.

Evaluating Flexible Modeling of Continuous Covariates in Inverse-Weighted Estimators.

Kyle RP, Moodie EEM, Klein MB, Abrahamowicz M.

Am J Epidemiol. 2019 Jun 1;188(6):1181-1191. doi: 10.1093/aje/kwz004.

PMID:
30649165
9.

Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.

Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferriere V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156. [Epub ahead of print]

PMID:
30649045
10.

Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross-sectional study.

Costiniuk CT, Nitulescu R, Saneei Z, Wasef N, Salahuddin S, Wasef D, Young J, de Castro C, Routy JP, Lebouché B, Cox J, Smith BM, Ambroise S, Pexos C, Patel M, Szabo J, Haraoui LP, de Pokomandy A, Tsoukas C, Falutz J, LeBlanc R, Giannakis A, Frenette C, Jenabian MA, Bourbeau J, Klein MB.

HIV Med. 2019 Mar;20(3):192-201. doi: 10.1111/hiv.12699. Epub 2019 Jan 8.

PMID:
30620136
11.

Evaluating the impact of health policies: using a difference-in-differences approach.

Saeed S, Moodie EEM, Strumpf EC, Klein MB.

Int J Public Health. 2019 May;64(4):637-642. doi: 10.1007/s00038-018-1195-2. Epub 2019 Jan 3. No abstract available.

PMID:
30607473
12.

Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.

Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A, Klein MB; Canadian Co-Infection Cohort Study.

Int J Drug Policy. 2019 Mar;65:41-49. doi: 10.1016/j.drugpo.2018.08.012. Epub 2018 Dec 26.

PMID:
30594080
13.

Liver-related events in HIV-infected persons with occult cirrhosis.

Benmassaoud A, Nitulescu R, Pembroke T, Halme AS, Ghali P, Deschenes M, Wong P, Klein MB, Sebastiani G.

Clin Infect Dis. 2018 Dec 18. doi: 10.1093/cid/ciy1082. [Epub ahead of print]

PMID:
30561558
14.

Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.

Kronfli N, Nitulescu R, Cox J, Moodie EE, Wong A, Cooper C, Gill J, Walmsley S, Martel-Laferrière V, Hull MW, Klein MB; Canadian Co-Infection Cohort Study.

J Int AIDS Soc. 2018 Nov;21(11):e25197. doi: 10.1002/jia2.25197.

15.

Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals.

Saeed S, Moodie EEM, Strumpf E, Gill J, Wong A, Cooper C, Walmsley S, Hull M, Martel-Laferriere V, Klein MB; Canadian Co-Infection Cohort Study Investigators.

J Viral Hepat. 2018 Dec;25(12):1507-1514. doi: 10.1111/jvh.12985. Epub 2018 Sep 27.

PMID:
30141236
16.

Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.

Zesiewicz T, Salemi JL, Perlman S, Sullivan KL, Shaw JD, Huang Y, Isaacs C, Gooch C, Lynch DR, Klein MB.

Neurodegener Dis Manag. 2018 Aug;8(4):233-242. doi: 10.2217/nmt-2018-0013. Epub 2018 Jul 27.

PMID:
30051753
17.

The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus.

McClymont E, Lee M, Raboud J, Coutlée F, Walmsley S, Lipsky N, Loutfy M, Trottier S, Smaill F, Klein MB, Harris M, Cohen J, Yudin MH, Wobeser W, Money D; CTN 236 HPV in HIV Study Team .

Clin Infect Dis. 2019 Feb 15;68(5):788-794. doi: 10.1093/cid/ciy575.

PMID:
29985988
18.

Injection drug use, food insecurity, and HIV-HCV co-infection: a longitudinal cohort analysis.

McLinden T, Moodie EEM, Harper S, Hamelin AM, Anema A, Aibibula W, Klein MB, Cox J.

AIDS Care. 2018 Oct;30(10):1322-1328. doi: 10.1080/09540121.2018.1465171. Epub 2018 May 1.

PMID:
29716392
19.

Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review.

Kronfli N, Linthwaite B, Kouyoumdjian F, Klein MB, Lebouché B, Sebastiani G, Cox J.

Int J Drug Policy. 2018 Jul;57:95-103. doi: 10.1016/j.drugpo.2018.04.003. Epub 2018 Apr 30.

PMID:
29715590
20.

Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression.

Almeida-Brasil CC, Moodie EEM, McLinden T, Hamelin AM, Walmsley SL, Rourke SB, Wong A, Klein MB, Cox J.

AIDS. 2018 Jun 19;32(10):1323-1332. doi: 10.1097/QAD.0000000000001822.

PMID:
29683846
21.

Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.

Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051.

22.

The Rocky Road to viral hepatitis elimination: assuring access to antiviral therapy for ALL coinfected patients from low- to high-income settings.

Lacombe K, Klein MB.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25073. doi: 10.1002/jia2.25073. No abstract available.

23.

Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.

Golizeh M, Melendez-Pena CE, Ward BJ, Saeed S, Santamaria C, Conway B, Cooper C, Klein MB, Ndao M; Canadian Co-Infection Cohort (CTN222).

PLoS One. 2018 Apr 2;13(4):e0195148. doi: 10.1371/journal.pone.0195148. eCollection 2018.

24.

Segmented generalized mixed effect models to evaluate health outcomes.

Saeed S, Moodie EEM, Strumpf EC, Klein MB.

Int J Public Health. 2018 May;63(4):547-551. doi: 10.1007/s00038-018-1091-9. Epub 2018 Mar 16. No abstract available.

PMID:
29549396
25.

Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis.

McLinden T, Moodie EEM, Hamelin AM, Harper S, Rossi C, Walmsley SL, Rourke SB, Cooper C, Klein MB, Cox J.

Drug Alcohol Depend. 2018 Apr 1;185:374-380. doi: 10.1016/j.drugalcdep.2017.12.031. Epub 2018 Feb 20.

PMID:
29544189
26.

Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV.

Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ Jr; North American AIDS Cohort Collaboration on Research and Design of IeDEA.

J Acquir Immune Defic Syndr. 2018 May 1;78(1):62-72. doi: 10.1097/QAI.0000000000001642.

27.

Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection.

Benmassaoud A, Ghali P, Cox J, Wong P, Szabo J, Deschenes M, Osikowicz M, Lebouche B, Klein MB, Sebastiani G.

PLoS One. 2018 Jan 30;13(1):e0191985. doi: 10.1371/journal.pone.0191985. eCollection 2018.

28.

Association between depressive symptoms, CD4 count and HIV viral suppression among HIV-HCV co-infected people.

Aibibula W, Cox J, Hamelin AM, Moodie EEM, Anema A, Klein MB, Brassard P; Canadian Co-infection Cohort Investigators.

AIDS Care. 2018 May;30(5):643-649. doi: 10.1080/09540121.2018.1431385. Epub 2018 Jan 28.

PMID:
29374972
29.

Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.

Rossi C, Saeed S, Cox J, Vachon ML, Martel-Laferrière V, Walmsley SL, Cooper C, Gill MJ, Hull M, Moodie EEM, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2018 Mar 27;32(6):751-759. doi: 10.1097/QAD.0000000000001750.

30.

Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.

Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study.

J Int AIDS Soc. 2017 Nov;20(3). doi: 10.1002/jia2.25013.

31.

Food insecurity may lead to incomplete HIV viral suppression and less immune reconstitution among HIV/hepatitis C virus-coinfected people.

Aibibula W, Cox J, Hamelin AM, Moodie E, Naimi AI, McLinden T, Klein MB, Brassard P.

HIV Med. 2018 Feb;19(2):123-131. doi: 10.1111/hiv.12561. Epub 2017 Nov 2.

PMID:
29094807
32.

Impact of Food Insecurity on Depressive Symptoms Among HIV-HCV Co-infected People.

Aibibula W, Cox J, Hamelin AM, Moodie EEM, Naimi AI, McLinden T, Klein MB, Brassard P; Canadian Co-infection Cohort Investigators.

AIDS Behav. 2017 Dec;21(12):3464-3472. doi: 10.1007/s10461-017-1942-z.

PMID:
29076031
33.

Japanese Leigh syndrome case treated with EPI-743.

Kouga T, Takagi M, Miyauchi A, Shimbo H, Iai M, Yamashita S, Murayama K, Klein MB, Miller G, Goto T, Osaka H.

Brain Dev. 2018 Feb;40(2):145-149. doi: 10.1016/j.braindev.2017.08.005. Epub 2017 Sep 12.

PMID:
28916229
34.

Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB.

J Int AIDS Soc. 2017 Jul 28;20(1):22146. doi: 10.7448/IAS.20.1.22146.

35.

Injection Drug Use, Unemployment, and Severe Food Insecurity Among HIV-HCV Co-Infected Individuals: A Mediation Analysis.

McLinden T, Moodie EEM, Hamelin AM, Harper S, Walmsley SL, Paradis G, Aibibula W, Klein MB, Cox J.

AIDS Behav. 2017 Dec;21(12):3496-3505. doi: 10.1007/s10461-017-1850-2.

PMID:
28726043
36.

Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada.

Benoit AC, Younger J, Beaver K, Jackson R, Loutfy M, Masching R, Nobis T, Nowgesic E, O'Brien-Teengs D, Whitebird W, Zoccole A, Hull M, Jaworsky D, Benson E, Rachlis A, Rourke SB, Burchell AN, Cooper C, Hogg RS, Klein MB, Machouf N, Montaner JSG, Tsoukas C, Raboud J.

Can J Public Health. 2017 Jun 16;108(2):e169-e175. doi: 10.17269/cjph.108.5708.

PMID:
28621653
37.

Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.

Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein MB, Sebastiani G.

J Hepatol. 2017 Oct;67(4):801-808. doi: 10.1016/j.jhep.2017.05.011. Epub 2017 May 18.

PMID:
28527666
38.

A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.

Moqueet N, Kanagaratham C, Gill MJ, Hull M, Walmsley S, Radzioch D, Saeed S, Platt RW, Klein MB; Canadian Co-infection Cohort Study (CTN 222).

PLoS One. 2017 May 3;12(5):e0176282. doi: 10.1371/journal.pone.0176282. eCollection 2017.

39.

A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada.

Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell AN, Cooper C, Hill T, Hull M, Klein MB, Loutfy M, Martin F, Machouf N, Montaner J, Nelson M, Raboud J, Rourke SB, Tsoukas C, Hogg RS, Sabin C; Canadian Observational Cohort (CANOC) - UK Collaborative HIV Cohort (UK CHIC) Collaboration.

HIV Med. 2017 Oct;18(9):655-666. doi: 10.1111/hiv.12505. Epub 2017 Apr 24.

40.

Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access.

Maponga TG, Matteau Matsha R, Morin S, Scheibe A, Swan T, Andrieux-Meyer I, Spearman CW, Klein MB, Rockstroh JK.

Hepatol Med Policy. 2017 Apr 20;2:8. doi: 10.1186/s41124-017-0025-0. eCollection 2017. Erratum in: Hepatol Med Policy. 2018 Sep 14;3:11.

41.

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.

Antoniou T, Szadkowski L, Walmsley S, Cooper C, Burchell AN, Bayoumi AM, Montaner JS, Loutfy M, Klein MB, Machouf N, Tsoukas C, Wong A, Hogg RS, Raboud J; Canadian Observational Cohort (CANOC) collaboration.

BMC Infect Dis. 2017 Apr 11;17(1):266. doi: 10.1186/s12879-017-2379-8.

42.

Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.

Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, Hull M, Chia J, Hogg RS, Moodie EE, Klein MB; Canadian Observational Cohort (CANOC) Collaboration.

BMC Infect Dis. 2017 Apr 4;17(1):246. doi: 10.1186/s12879-017-2350-8.

43.

Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV.

Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators.

Clin Infect Dis. 2017 May 1;64(9):1154-1162. doi: 10.1093/cid/cix126.

44.

Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.

Martel-Laferrière V, Nitulescu R, Cox J, Cooper C, Tyndall M, Rouleau D, Walmsley S, Wong L, Klein MB; Canadian Co-infection Cohort Study Investigators.

BMC Infect Dis. 2017 Jan 17;17(1):80. doi: 10.1186/s12879-017-2196-0.

45.

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.

Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; Canadian Network on Hepatitis C (CanHepC).

CMAJ Open. 2016 Oct 14;4(4):E605-E614. doi: 10.9778/cmajo.20160008. eCollection 2016 Oct-Dec.

46.

A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.

Benoit AC, Younger J, Beaver K, Jackson R, Loutfy M, Masching R, Nobis T, Nowgesic E, O'Brien-Teengs D, Whitebird W, Zoccole A, Hull M, Jaworsky D, Rachlis A, Rourke S, Burchell AN, Cooper C, Hogg R, Klein MB, Machouf N, Montaner J, Tsoukas C, Raboud J; Building Bridges; Canadian Observational Cohort Collaboration.

Antivir Ther. 2017;22(4):325-335. doi: 10.3851/IMP3114. Epub 2016 Dec 7.

PMID:
27925609
47.

A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy.

Gillis J, Loutfy M, Bayoumi AM, Antoniou T, Burchell AN, Walmsley S, Cooper C, Klein MB, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Hogg R, Raboud J; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):531-539.

48.

The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C.

van Buuren N, Fradette L, Grebely J, King A, Krajden M, MacParland SA, Marshall A, Saeed S, Wilson J, Klein MB, Sagan SM.

Can J Gastroenterol Hepatol. 2016;2016:7603526. Epub 2016 Oct 24.

49.

Association Between Food Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis.

Aibibula W, Cox J, Hamelin AM, McLinden T, Klein MB, Brassard P.

AIDS Behav. 2017 Mar;21(3):754-765. doi: 10.1007/s10461-016-1605-5. Review.

PMID:
27837425
50.

Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.

Vuille-Lessard É, Lebouché B, Lennox L, Routy JP, Costiniuk CT, Pexos C, Giannakis A, Szabo J, Klein MB, Sebastiani G.

AIDS. 2016 Nov 13;30(17):2635-2643.

PMID:
27603289

Supplemental Content

Loading ...
Support Center